#News : A #biosimilar was approved by the FDA today for #psoriaticarthritis and #plaquepsoriasis . We'reproud to continue providing access to treatments for patients living with inflammatory conditions in partnership with Alvotech. ow.ly/fAjA50RhGs2

We are honored to join American Academy of Neurology at #AAN2024 to present new data on Huntington's disease (HD). Read about the data here: bit.ly/3UkdkSn

As part of our commitment to innovation in #schizophrenia treatment, we presented our latest research evaluating a long-acting treatment option at the Schizophrenia International Research Society annual meeting.

Learn more: bit.ly/4cXIJRU

#SIRS2024

Teva announced a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications.

Learn more here: bit.ly/3xo8ryC

#Tevapharm #Oncology #PivotToGrowth

Today Teva announced a clinical collaboration agreement with Launch Therapeutics and a strategic funding development agreement with Abingworth to accelerate development of our dual-action asthma rescue inhaler respiratory program.
Read more: bit.ly/49rfbcs #Asthma

Today, the FDA approved an interchangeable #biosimilar that may provide broader access to needed medicines for patients with autoimmune diseases. Along with our partner Alvotech, we are proud of this milestone with more to come. Read more: ow.ly/YLB050QHqaw #TevaUSA

#NEWS : We’re sharing new data about our innovative antibody candidate for #IBD at the European Crohn’s and Colitis Organisation (ECCO) Annual Congress.

Read more about this new data here: ow.ly/WI2R50QFGGs

#TevaUSA #ECCO24 #CrohnsDisease #UlcerativeColitis

Americans rely heavily on access to affordable generic drugs. Yet, millions are struggling to fill their prescriptions due to the drug shortage crisis.

This issue is not an easy one to solve, but we remain committed to working with our industry partners to find a solution.

Teva CEO, Richard Francis, shared his perspective with Yahoo Finance on our Q4 and full-year 2023 performance.

Watch the interview here: yhoo.it/3Os0fTv

$Teva #QuarterlyResults #Earnings

As the world's largest generic drug maker, Teva Pharmaceuticals is looking to drive even more growth following an earnings beat in Q4 🧪

CEO Richard Francis explains why the company's divesting its active pharmaceutical ingredient business.

Teva and Biolojic announce an exclusive license agreement to develop a therapeutic antibody for atopic dermatitis and asthma.

Read our press release here: ow.ly/KW3k50QiJyV

📢We are thrilled to have Richard Francis, President and CEO, at Teva Pharmaceuticals as a Keynote Speaker at Fierce JPM Week 2024 on Jan 9-10th!

🎟️Register Now! ➡ ow.ly/q2RG50QbIC7
#FierceJPMWeek #WeAreFierce #FierceBiotech #FiercePharma #JPMWeek